Tobira Therapeutics, Inc. clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 12 studies whose lead sponsor is Tobira Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 10, 2022.

Studies

Recruiting first, then most recently updated. Showing 12 of 12. All AbbVie studies →

• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03028740Phase 3

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic SteatohepatitisTerminatedNCT03059446Phase 2

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLDCompletedNCT02330549Phase 2

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver FibrosisCompletedNCT02217475Phase 2

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing CholangitisCompletedNCT02653625Phase 2

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and DigoxinCompletedNCT02685462Phase 1

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in CombinationCompletedNCT02684799Phase 1

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in CombinationCompletedNCT02342067Phase 1

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic ImpairmentCompletedNCT02120547Phase 1

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamCompletedNCT01827540Phase 1

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve PatientsCompletedNCT01092104Phase 1/2

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie

• Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic VirusCompletedNCT01338883Phase 2

  Sponsor listed in the registry: Tobira Therapeutics, Inc. · First submitted before Tobira Therapeutics, Inc. became part of AbbVie